{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:37:00Z","timestamp":1792701420441,"version":"4.5.0"},"reference-count":158,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,11,27]],"date-time":"2017-11-27T00:00:00Z","timestamp":1511740800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,11,27]],"date-time":"2017-11-27T00:00:00Z","timestamp":1511740800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1038\/nrneph.2017.155","type":"journal-article","created":{"date-parts":[[2017,11,27]],"date-time":"2017-11-27T05:40:26Z","timestamp":1511761226000},"page":"57-70","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":291,"title":["Dyslipidaemia in nephrotic syndrome: mechanisms and treatment"],"prefix":"10.1038","volume":"14","author":[{"given":"Shipra","family":"Agrawal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua J.","family":"Zaritsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Fornoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Smoyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,27]]},"reference":[{"key":"BFnrneph2017155_CR1","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nrneph.2012.115","volume":"8","author":"LA Greenbaum","year":"2012","unstructured":"Greenbaum, L. A., Benndorf, R. & Smoyer, W. E. Childhood nephrotic syndrome \u2014 current and future therapies. Nat. Rev. Nephrol. 8, 445\u2013458 (2012).","journal-title":"Nat. Rev. Nephrol."},{"key":"BFnrneph2017155_CR2","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1136\/bmj.39576.709711.80","volume":"336","author":"RP Hull","year":"2008","unstructured":"Hull, R. P. & Goldsmith, D. J. Nephrotic syndrome in adults. BMJ 336, 1185\u20131189 (2008).","journal-title":"BMJ"},{"key":"BFnrneph2017155_CR3","first-page":"731","volume-title":"Pediatric Nephrology","author":"AG Clark","year":"1998","unstructured":"Clark, A. G. & Barratt, T. M. in Pediatric Nephrology (eds Barratt, T. M., Avner, E. D. & Harmon, W. E.) 731\u2013747 (Lippincott Williams & Wilkins, 1998)."},{"key":"BFnrneph2017155_CR4","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0031-3955(16)34218-3","volume":"89","author":"PT McEnery","year":"1982","unstructured":"McEnery, P. T. & Strife, C. F. Nephrotic syndrome in childhood. Management and treatment in patients with minimal change disease, mesangial proliferation, or focal glomerulosclerosis. Pediatr. Clin. North Am. 89, 875\u2013894 (1982).","journal-title":"Pediatr. Clin. North Am."},{"key":"BFnrneph2017155_CR5","first-page":"1247","volume-title":"Pediatric Kidney Disease","author":"MA Nash","year":"1992","unstructured":"Nash, M. A., Edelmann, C. M. J., Bernstein, J. & Barnett, H. L. in Pediatric Kidney Disease (ed. Edelmann, C. M. J.) 1247\u20131266 (Little, 1992)."},{"key":"BFnrneph2017155_CR6","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/S0272-6386(99)70384-7","volume":"34","author":"C Ponticelli","year":"1999","unstructured":"Ponticelli, C. et al. Can prolonged treatment improve the prognosis in adults with focal segmental glomerulosclerosis? Am. J. Kidney Dis 34, 618\u2013625 (1999).","journal-title":"Am. J. Kidney Dis"},{"key":"BFnrneph2017155_CR7","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1007\/s00467-009-1282-y","volume":"24","author":"N MacHardy","year":"2009","unstructured":"MacHardy, N. et al. Management patterns of childhood-onset nephrotic syndrome. Pediatr. Nephrol. 24, 2193\u20132201 (2009).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2017155_CR8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.krcp.2012.04.323","volume":"31","author":"WY Ding","year":"2012","unstructured":"Ding, W. Y. & Saleem, M. A. Current concepts of the podocyte in nephrotic syndrome. Kidney Res. Clin. Pract. 31, 87\u201393 (2012).","journal-title":"Kidney Res. Clin. Pract."},{"key":"BFnrneph2017155_CR9","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S0272-6386(12)80369-6","volume":"23","author":"RC Harris","year":"1994","unstructured":"Harris, R. C. & Ismail, N. Extrarenal complications of the nephrotic syndrome. Am. J. Kidney Dis 23, 477\u2013497 (1994).","journal-title":"Am. J. Kidney Dis"},{"key":"BFnrneph2017155_CR10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0272-6386(87)80170-1","volume":"10","author":"JS Cameron","year":"1987","unstructured":"Cameron, J. S. The nephrotic syndrome and its complications. Am. J. Kidney Dis 10, 157\u2013171 (1987).","journal-title":"Am. J. Kidney Dis"},{"key":"BFnrneph2017155_CR11","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/ki.1985.149","volume":"28","author":"F Llach","year":"1985","unstructured":"Llach, F. Hypercoagulability, renal vein thrombosis, and other thrombotic complications of nephrotic syndrome. Kidney Int. 28, 429\u2013439 (1985).","journal-title":"Kidney Int."},{"key":"BFnrneph2017155_CR12","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.2215\/CJN.06620615","volume":"10","author":"MN Rheault","year":"2015","unstructured":"Rheault, M. N. et al. AKI in children hospitalized with nephrotic syndrome. Clin. J. Am. Soc. Nephrol. 10, 2110\u20132118 (2015).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2017155_CR13","doi-asserted-by":"publisher","first-page":"85","DOI":"10.4103\/2229-5151.183019","volume":"6","author":"HF Al-Azzawi","year":"2016","unstructured":"Al-Azzawi, H. F., Obi, O. C., Safi, J. & Song, M. Nephrotic syndrome-induced thromboembolism in adults. Int. J. Crit. Illn. Inj. Sci. 6, 85\u201388 (2016).","journal-title":"Int. J. Crit. Illn. Inj. Sci."},{"key":"BFnrneph2017155_CR14","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2215\/CJN.10131011","volume":"7","author":"BA Kerlin","year":"2012","unstructured":"Kerlin, B. A., Ayoob, R. & Smoyer, W. E. Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease. Clin. J. Am. Soc. Nephrol. 7, 513\u2013520 (2012).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2017155_CR15","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s00467-013-2525-5","volume":"29","author":"BA Kerlin","year":"2014","unstructured":"Kerlin, B. A., Haworth, K. & Smoyer, W. E. Venous thromboembolism in pediatric nephrotic syndrome. Pediatr. Nephrol. 29, 989\u2013997 (2014).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2017155_CR16","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1056\/NEJMcibr1209459","volume":"368","author":"J Loscalzo","year":"2013","unstructured":"Loscalzo, J. Venous thrombosis in the nephrotic syndrome. N. Engl. J. Med. 368, 956\u2013958 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2017155_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.kint.2016.02.026","volume":"90","author":"ND Vaziri","year":"2016","unstructured":"Vaziri, N. D. Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences. Kidney Int. 90, 41\u201352 (2016).","journal-title":"Kidney Int."},{"key":"BFnrneph2017155_CR18","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1056\/NEJM199008303230905","volume":"323","author":"J Joven","year":"1990","unstructured":"Joven, J. et al. Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N. Engl. J. Med. 323, 579\u2013584 (1990).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2017155_CR19","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/dmrr.895","volume":"24","author":"H Zhou","year":"2008","unstructured":"Zhou, H., Tan, K. C., Shiu, S. W. & Wong, Y. Cellular cholesterol efflux to serum is impaired in diabetic nephropathy. Diabetes Metab. Res. Rev. 24, 617\u2013623 (2008).","journal-title":"Diabetes Metab. Res. Rev."},{"key":"BFnrneph2017155_CR20","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1111\/j.1523-1755.1998.00831.x","volume":"53","author":"MG van der Velden","year":"1998","unstructured":"de Sain- van der Velden, M. G. et al. Increased VLDL in nephrotic patients results from a decreased catabolism while increased LDL results from increased synthesis. Kidney Int. 53, 994\u20131001 (1998).","journal-title":"Kidney Int."},{"key":"BFnrneph2017155_CR21","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1172\/JCI111548","volume":"74","author":"DW Garber","year":"1984","unstructured":"Garber, D. W., Gottlieb, B. A., Marsh, J. B. & Sparks, C. E. Catabolism of very low density lipoproteins in experimental nephrosis. J. Clin. Invest. 74, 1375\u20131383 (1984).","journal-title":"J. Clin. Invest."},{"key":"BFnrneph2017155_CR22","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1172\/JCI114750","volume":"86","author":"RW Davies","year":"1990","unstructured":"Davies, R. W., Staprans, I., Hutchison, F. N. & Kaysen, G. A. Proteinuria, not altered albumin metabolism, affects hyperlipidemia in the nephrotic rat. J. Clin. Invest. 86, 600\u2013605 (1990).","journal-title":"J. Clin. Invest."},{"key":"BFnrneph2017155_CR23","doi-asserted-by":"publisher","first-page":"F262","DOI":"10.1152\/ajprenal.00099.2005","volume":"290","author":"ND Vaziri","year":"2006","unstructured":"Vaziri, N. D. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am. J. Physiol. Renal Physiol. 290, F262\u2013F272 (2006).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"BFnrneph2017155_CR24","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1681\/ASN.2014030267","volume":"25","author":"C Mace","year":"2014","unstructured":"Mace, C. & Chugh, S. S. Nephrotic syndrome: components, connections, and angiopoietin-like 4-related therapeutics. J. Am. Soc. Nephrol. 25, 2393\u20132398 (2014).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2017155_CR25","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1001\/archinte.164.6.659","volume":"164","author":"DS Keith","year":"2004","unstructured":"Keith, D. S., Nichols, G. A., Gullion, C. M., Brown, J. B. & Smith, D. H. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch. Intern. Med. 164, 659\u2013663 (2004).","journal-title":"Arch. Intern. Med."},{"key":"BFnrneph2017155_CR26","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1161\/CIRCRESAHA.117.310700","volume":"120","author":"C Yeang","year":"2017","unstructured":"Yeang, C., Gordts, P. L. & Tsimikas, S. Novel lipoprotein(a) catabolism pathway via apolipoprotein(a) recycling: Adding the plasminogen receptor PlgRKT to the list. Circ. Res. 120, 1050\u20131052 (2017).","journal-title":"Circ. Res."},{"key":"BFnrneph2017155_CR27","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1161\/CIRCRESAHA.116.310272","volume":"120","author":"M Sharma","year":"2017","unstructured":"Sharma, M., Redpath, G. M., Williams, M. J. & McCormick, S. P. Recycling of apolipoprotein(a) after PlgRKT-mediated endocytosis of lipoprotein(a). Circ. Res. 120, 1091\u20131102 (2017).","journal-title":"Circ. Res."},{"key":"BFnrneph2017155_CR28","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1161\/ATVBAHA.116.308704","volume":"37","author":"PM Moriarty","year":"2017","unstructured":"Moriarty, P. M., Varvel, S. A., Gordts, P. L., McConnell, J. P. & Tsimikas, S. Lipoprotein(a) mass levels increase significantly according to APOE genotype: an analysis of 431 239 patients. Arterioscler. Thromb. Vasc. Biol. 37, 580\u2013588 (2017).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrneph2017155_CR29","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1194\/jlr.R200015-JLR200","volume":"43","author":"M Merkel","year":"2002","unstructured":"Merkel, M., Eckel, R. H. & Goldberg, I. J. Lipoprotein lipase: genetics, lipid uptake, and regulation. J. Lipid Res. 43, 1997\u20132006 (2002).","journal-title":"J. Lipid Res."},{"key":"BFnrneph2017155_CR30","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1194\/jlr.M072520","volume":"58","author":"CM Allan","year":"2017","unstructured":"Allan, C. M. et al. Mobility of \u201cHSPG-bound\u201d LPL explains how LPL is able to reach GPIHBP1 on capillaries. J. Lipid Res. 58, 216\u2013225 (2017).","journal-title":"J. Lipid Res."},{"key":"BFnrneph2017155_CR31","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.cmet.2010.04.016","volume":"12","author":"BS Davies","year":"2010","unstructured":"Davies, B. S. et al. GPIHBP1 is responsible for the entry of lipoprotein lipase into capillaries. Cell Metab. 12, 42\u201352 (2010).","journal-title":"Cell Metab."},{"key":"BFnrneph2017155_CR32","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s10157-011-0549-3","volume":"16","author":"ND Vaziri","year":"2012","unstructured":"Vaziri, N. D., Yuan, J., Ni, Z., Nicholas, S. B. & Norris, K. C. Lipoprotein lipase deficiency in chronic kidney disease is accompanied by down-regulation of endothelial GPIHBP1 expression. Clin. Exp. Nephrol. 16, 238\u2013243 (2012).","journal-title":"Clin. Exp. Nephrol."},{"key":"BFnrneph2017155_CR33","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/S0140-6736(82)91513-6","volume":"2","author":"JF Moorhead","year":"1982","unstructured":"Moorhead, J. F., Chan, M. K., El-Nahas, M. & Varghese, Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 2, 1309\u20131311 (1982).","journal-title":"Lancet"},{"key":"BFnrneph2017155_CR34","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nm.3396","volume":"20","author":"LC Clement","year":"2014","unstructured":"Clement, L. C. et al. Circulating angiopoietin-like 4 links proteinuria with hypertriglyceridemia in nephrotic syndrome. Nat. Med. 20, 37\u201346 (2014).","journal-title":"Nat. Med."},{"key":"BFnrneph2017155_CR35","doi-asserted-by":"publisher","first-page":"17450","DOI":"10.1073\/pnas.0604026103","volume":"103","author":"V Sukonina","year":"2006","unstructured":"Sukonina, V., Lookene, A., Olivecrona, T. & Olivecrona, G. Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue. Proc. Natl Acad. Sci. USA 103, 17450\u201317455 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneph2017155_CR36","doi-asserted-by":"publisher","first-page":"28524","DOI":"10.1074\/jbc.M113.497602","volume":"288","author":"MJ Lafferty","year":"2013","unstructured":"Lafferty, M. J., Bradford, K. C., Erie, D. A. & Neher, S. B. Angiopoietin-like protein 4 inhibition of lipoprotein lipase: evidence for reversible complex formation. J. Biol. Chem. 288, 28524\u201328534 (2013).","journal-title":"J. Biol. Chem."},{"key":"BFnrneph2017155_CR37","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1038\/ki.1997.242","volume":"51","author":"K Liang","year":"1997","unstructured":"Liang, K. & Vaziri, N. D. Acquired VLDL receptor deficiency in experimental nephrosis. Kidney Int. 51, 1761\u20131765 (1997).","journal-title":"Kidney Int."},{"key":"BFnrneph2017155_CR38","doi-asserted-by":"publisher","first-page":"F662","DOI":"10.1152\/ajprenal.00046.2008","volume":"295","author":"Y Zhou","year":"2008","unstructured":"Zhou, Y. et al. Expression profiling of hepatic genes associated with lipid metabolism in nephrotic rats. Am. J. Physiol. Renal Physiol. 295, F662\u2013F671 (2008).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"BFnrneph2017155_CR39","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1046\/j.1523-1755.2001.00506.x","volume":"59","author":"MP O'Donnell","year":"2001","unstructured":"O'Donnell, M. P. Mechanisms and clinical importance of hypertriglyceridemia in the nephrotic syndrome. Kidney Int. 59, 380\u2013382 (2001).","journal-title":"Kidney Int."},{"key":"BFnrneph2017155_CR40","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0021-9150(80)90025-8","volume":"35","author":"ML Kashyap","year":"1980","unstructured":"Kashyap, M. L. et al. Apolipoprotein CII and lipoprotein lipase in human nephrotic syndrome. Atherosclerosis 35, 29\u201340 (1980).","journal-title":"Atherosclerosis"},{"key":"BFnrneph2017155_CR41","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/0009-8981(81)90034-6","volume":"117","author":"T Ohta","year":"1981","unstructured":"Ohta, T. & Matsuda, I. Lipid and apolipoprotein levels in patients with nephrotic syndrome. Clin. Chim. Acta 117, 133\u2013143 (1981).","journal-title":"Clin. Chim. Acta"},{"key":"BFnrneph2017155_CR42","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1681\/ASN.2015111228","volume":"28","author":"SH Nasr","year":"2017","unstructured":"Nasr, S. H. et al. Novel type of renal amyloidosis derived from apolipoprotein-CII. J. Am. Soc. Nephrol. 28, 439\u2013445 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2017155_CR43","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1194\/jlr.M600367-JLR200","volume":"48","author":"N Tentolouris","year":"2007","unstructured":"Tentolouris, N. et al. High postprandial triglyceridemia in patients with type 2 diabetes and microalbuminuria. J. Lipid Res. 48, 218\u2013225 (2007).","journal-title":"J. Lipid Res."},{"key":"BFnrneph2017155_CR44","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s40259-017-0220-y","volume":"31","author":"B Di Bartolo","year":"2017","unstructured":"Di Bartolo, B., Scherer, D. J., Brown, A., Psaltis, P. J. & Nicholls, S. J. PCSK9 inhibitors in hyperlipidemia: current status and clinical outlook. BioDrugs 31, 167\u2013174 (2017).","journal-title":"BioDrugs"},{"key":"BFnrneph2017155_CR45","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/nrneph.2016.111","volume":"12","author":"AW Morris","year":"2016","unstructured":"Morris, A. W. Nephrotic syndrome: PCSK9: a target for hypercholesterolaemia in nephrotic syndrome. Nat. Rev. Nephrol. 12, 510 (2016).","journal-title":"Nat. Rev. Nephrol."},{"key":"BFnrneph2017155_CR46","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s11255-017-1505-2","volume":"49","author":"P Pavlakou","year":"2017","unstructured":"Pavlakou, P., Liberopoulos, E., Dounousi, E. & Elisaf, M. PCSK9 in chronic kidney disease. Int. Urol. Nephrol. 49, 1015\u20131024 (2017).","journal-title":"Int. Urol. Nephrol."},{"key":"BFnrneph2017155_CR47","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1161\/CIRCULATIONAHA.115.020912","volume":"134","author":"ME Haas","year":"2016","unstructured":"Haas, M. E. et al. The role of proprotein convertase subtilisin\/kexin type 9 in nephrotic syndrome-associated hypercholesterolemia. Circulation 134, 61\u201372 (2016).","journal-title":"Circulation"},{"key":"BFnrneph2017155_CR48","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/0026-0495(90)90074-M","volume":"39","author":"GL Warwick","year":"1990","unstructured":"Warwick, G. L. et al. Low-density lipoprotein metabolism in the nephrotic syndrome. Metabolism 39, 187\u2013192 (1990).","journal-title":"Metabolism"},{"key":"BFnrneph2017155_CR49","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1038\/ki.1995.500","volume":"48","author":"ND Vaziri","year":"1995","unstructured":"Vaziri, N. D. & Liang, K. H. Hepatic HMG-CoA reductase gene expression during the course of puromycin-induced nephrosis. Kidney Int. 48, 1979\u20131985 (1995).","journal-title":"Kidney Int."},{"key":"BFnrneph2017155_CR50","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa043175","volume":"353","author":"S Tsimikas","year":"2005","unstructured":"Tsimikas, S. et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N. Engl. J. Med. 353, 46\u201357 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2017155_CR51","doi-asserted-by":"publisher","first-page":"263","DOI":"10.7326\/0003-4819-119-4-199308150-00002","volume":"119","author":"C Wanner","year":"1993","unstructured":"Wanner, C. et al. Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome. Ann. Intern. Med. 119, 263\u2013269 (1993).","journal-title":"Ann. Intern. Med."},{"key":"BFnrneph2017155_CR52","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/S0092-8674(01)00238-0","volume":"104","author":"CK Glass","year":"2001","unstructured":"Glass, C. K. & Witztum, J. L. Atherosclerosis: the road ahead. Cell 104, 503\u2013516 (2001).","journal-title":"Cell"},{"key":"BFnrneph2017155_CR53","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/j.1365-2362.1977.tb01652.x","volume":"7","author":"E Gherardi","year":"1977","unstructured":"Gherardi, E., Rota, E., Calandra, S., Genova, R. & Tamborino, A. Relationship among the concentrations of serum lipoproteins and changes in their chemical composition in patients with untreated nephrotic syndrome. Eur. J. Clin. Invest. 7, 563\u2013570 (1977).","journal-title":"Eur. J. Clin. Invest."},{"key":"BFnrneph2017155_CR54","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1161\/ATVBAHA.108.179283","volume":"30","author":"L Yvan-Charvet","year":"2010","unstructured":"Yvan-Charvet, L., Wang, N. & Tall, A. R. Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. Arterioscler. Thromb. Vasc. Biol. 30, 139\u2013143 (2010).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrneph2017155_CR55","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1161\/ATVBAHA.106.136325","volume":"27","author":"RS Birjmohun","year":"2007","unstructured":"Birjmohun, R. S. et al. High-density lipoprotein attenuates inflammation and coagulation response on endotoxin challenge in humans. Arterioscler. Thromb. Vasc. Biol. 27, 1153\u20131158 (2007).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrneph2017155_CR56","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1161\/ATVBAHA.108.168690","volume":"28","author":"AJ Murphy","year":"2008","unstructured":"Murphy, A. J. et al. High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler. Thromb. Vasc. Biol. 28, 2071\u20132077 (2008).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrneph2017155_CR57","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1038\/89986","volume":"7","author":"IS Yuhanna","year":"2001","unstructured":"Yuhanna, I. S. et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat. Med. 7, 853\u2013857 (2001).","journal-title":"Nat. Med."},{"key":"BFnrneph2017155_CR58","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/0021-9150(85)90181-9","volume":"54","author":"E Muls","year":"1985","unstructured":"Muls, E., Rosseneu, M., Daneels, R., Schurgers, M. & Boelaert, J. Lipoprotein distribution and composition in the human nephrotic syndrome. Atherosclerosis 54, 225\u2013237 (1985).","journal-title":"Atherosclerosis"},{"key":"BFnrneph2017155_CR59","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nrneph.2015.180","volume":"12","author":"ND Vaziri","year":"2016","unstructured":"Vaziri, N. D. HDL abnormalities in nephrotic syndrome and chronic kidney disease. Nat. Rev. Nephrol. 12, 37\u201347 (2016).","journal-title":"Nat. Rev. Nephrol."},{"key":"BFnrneph2017155_CR60","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.1172\/JCI85939","volume":"126","author":"CE Pedigo","year":"2016","unstructured":"Pedigo, C. E. et al. Local TNF causes NFATc1-dependent cholesterol-mediated podocyte injury. J. Clin. Invest. 126, 3336\u20133350 (2016).","journal-title":"J. Clin. Invest."},{"key":"BFnrneph2017155_CR61","first-page":"183","volume":"1","author":"W Jao","year":"1973","unstructured":"Jao, W., Lewy, P., Norris, S. H., Pollak, V. E. & Pirani, C. L. Lipoid nephrosis: a reassessment. Perspect. Nephrol. Hypertens. 1, 183\u2013198 (1973).","journal-title":"Perspect. Nephrol. Hypertens."},{"key":"BFnrneph2017155_CR62","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1007\/s10157-013-0930-5","volume":"18","author":"E Muso","year":"2014","unstructured":"Muso, E. Beneficial effect of LDL-apheresis in refractory nephrotic syndrome. Clin. Exp. Nephrol. 18, 286\u2013290 (2014).","journal-title":"Clin. Exp. Nephrol."},{"key":"BFnrneph2017155_CR63","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/0002-9343(77)90874-9","volume":"62","author":"T Gordon","year":"1977","unstructured":"Gordon, T., Castelli, W. P., Hjortland, M. C., Kannel, W. B. & Dawber, T. R. High density lipoprotein as a protective factor against coronary heart disease: the Framingham study. Am. J. Med. 62, 707\u2013714 (1977).","journal-title":"Am. J. Med."},{"key":"BFnrneph2017155_CR64","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1194\/jlr.R039297","volume":"55","author":"KA Rye","year":"2014","unstructured":"Rye, K. A. & Barter, P. J. Cardioprotective functions of HDLs. J. Lipid Res. 55, 168\u2013179 (2014).","journal-title":"J. Lipid Res."},{"key":"BFnrneph2017155_CR65","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","volume":"365","author":"WE Boden","year":"2011","unstructured":"Boden, W. E. et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365, 2255\u20132267 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2017155_CR66","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","volume":"357","author":"PJ Barter","year":"2007","unstructured":"Barter, P. J. et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357, 2109\u20132122 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2017155_CR67","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.bbalip.2011.09.008","volume":"1821","author":"JD Brunzell","year":"2012","unstructured":"Brunzell, J. D., Zambon, A. & Deeb, S. S. The effect of hepatic lipase on coronary artery disease in humans is influenced by the underlying lipoprotein phenotype. Biochim. Biophys. Acta 1821, 365\u2013372 (2012).","journal-title":"Biochim. Biophys. Acta"},{"key":"BFnrneph2017155_CR68","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","volume":"380","author":"BF Voight","year":"2012","unstructured":"Voight, B. F. et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 380, 572\u2013580 (2012).","journal-title":"Lancet"},{"key":"BFnrneph2017155_CR69","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01841684 (2015)."},{"key":"BFnrneph2017155_CR70","unstructured":"Brooks, M. REVEAL: CETP inhibitor anacetrapib meets primary end point. Medscape Nephrology http:\/\/www.medscape.com\/viewarticle\/882173 (2017)."},{"key":"BFnrneph2017155_CR71","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S0046-8177(87)80238-1","volume":"18","author":"T Faraggiana","year":"1987","unstructured":"Faraggiana, T. & Churg, J. Renal lipidoses: a review. Hum. Pathol. 18, 661\u2013679 (1987).","journal-title":"Hum. Pathol."},{"key":"BFnrneph2017155_CR72","doi-asserted-by":"publisher","first-page":"e0150083","DOI":"10.1371\/journal.pone.0150083","volume":"11","author":"A Ossoli","year":"2016","unstructured":"Ossoli, A. et al. Lipoprotein X causes renal disease in LCAT deficiency. PLoS ONE 11, e0150083 (2016).","journal-title":"PLoS ONE"},{"key":"BFnrneph2017155_CR73","first-page":"101","volume":"78","author":"VJ Ferrans","year":"1975","unstructured":"Ferrans, V. J. & Fredrickson, D. S. The pathology of Tangier disease. A light and electron microscopic study. Am. J. Pathol. 78, 101\u2013158 (1975).","journal-title":"Am. J. Pathol."},{"key":"BFnrneph2017155_CR74","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1172\/JCI89626","volume":"127","author":"S Lovric","year":"2017","unstructured":"Lovric, S. et al. Mutations in sphingosine-1-phosphate lyase cause nephrosis with ichthyosis and adrenal insufficiency. J. Clin. Invest. 127, 912\u2013928 (2017).","journal-title":"J. Clin. Invest."},{"key":"BFnrneph2017155_CR75","doi-asserted-by":"publisher","first-page":"85ra46","DOI":"10.1126\/scitranslmed.3002231","volume":"3","author":"A Fornoni","year":"2011","unstructured":"Fornoni, A. et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci. Transl Med. 3, 85ra46 (2011).","journal-title":"Sci. Transl Med."},{"key":"BFnrneph2017155_CR76","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/art.21329","volume":"53","author":"HK Choi","year":"2005","unstructured":"Choi, H. K. & Seeger, J. D. Glucocorticoid use and serum lipid levels in US adults: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 53, 528\u2013535 (2005).","journal-title":"Arthritis Rheum."},{"key":"BFnrneph2017155_CR77","first-page":"1264","volume":"21","author":"KH Leong","year":"1994","unstructured":"Leong, K. H., Koh, E. T., Feng, P. H. & Boey, M. L. Lipid profiles in patients with systemic lupus erythematosus. J. Rheumatol 21, 1264\u20131267 (1994).","journal-title":"J. Rheumatol"},{"key":"BFnrneph2017155_CR78","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1136\/ard.51.2.152","volume":"51","author":"AJ MacGregor","year":"1992","unstructured":"MacGregor, A. J. et al. Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus. Ann. Rheum. Dis. 51, 152\u2013155 (1992).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrneph2017155_CR79","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1677\/JOE-08-0054","volume":"197","author":"DP Macfarlane","year":"2008","unstructured":"Macfarlane, D. P., Forbes, S. & Walker, B. R. Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome. J. Endocrinol. 197, 189\u2013204 (2008).","journal-title":"J. Endocrinol."},{"key":"BFnrneph2017155_CR80","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1097\/00007890-200203150-00021","volume":"73","author":"F Vincenti","year":"2002","unstructured":"Vincenti, F., Jensik, S. C., Filo, R. S., Miller, J. & Pirsch, J. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 73, 775\u2013782 (2002).","journal-title":"Transplantation"},{"key":"BFnrneph2017155_CR81","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1097\/00007890-199708150-00012","volume":"64","author":"AD Mayer","year":"1997","unstructured":"Mayer, A. D. et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 64, 436\u2013443 (1997).","journal-title":"Transplantation"},{"key":"BFnrneph2017155_CR82","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/nm0907-1015","volume":"13","author":"SP Jackson","year":"2007","unstructured":"Jackson, S. P. & Calkin, A. C. The clot thickens \u2014 oxidized lipids and thrombosis. Nat. Med. 13, 1015\u20131016 (2007).","journal-title":"Nat. Med."},{"key":"BFnrneph2017155_CR83","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/nm1626","volume":"13","author":"EA Podrez","year":"2007","unstructured":"Podrez, E. A. et al. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat. Med. 13, 1086\u20131095 (2007).","journal-title":"Nat. Med."},{"key":"BFnrneph2017155_CR84","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s11906-012-0250-2","volume":"14","author":"L Gyebi","year":"2012","unstructured":"Gyebi, L., Soltani, Z. & Reisin, E. Lipid nephrotoxicity: new concept for an old disease. Curr. Hypertens. Rep. 14, 177\u2013181 (2012).","journal-title":"Curr. Hypertens. Rep."},{"key":"BFnrneph2017155_CR85","doi-asserted-by":"publisher","first-page":"F640","DOI":"10.1152\/ajprenal.00001.2002","volume":"283","author":"ME Thomas","year":"2002","unstructured":"Thomas, M. E., Harris, K. P., Walls, J., Furness, P. N. & Brunskill, N. J. Fatty acids exacerbate tubulointerstitial injury in protein-overload proteinuria. Am. J. Physiol. Renal Physiol. 283, F640\u2013F647 (2002).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"BFnrneph2017155_CR86","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1046\/j.1523-1755.2002.00618.x","volume":"62","author":"A Kamijo","year":"2002","unstructured":"Kamijo, A. et al. Urinary free fatty acids bound to albumin aggravate tubulointerstitial damage. Kidney Int. 62, 1628\u20131637 (2002).","journal-title":"Kidney Int."},{"key":"BFnrneph2017155_CR87","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1681\/ASN.2008070694","volume":"20","author":"B Schermer","year":"2009","unstructured":"Schermer, B. & Benzing, T. Lipid-protein interactions along the slit diaphragm of podocytes. J. Am. Soc. Nephrol. 20, 473\u2013478 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2017155_CR88","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/S0272-6386(12)70171-3","volume":"22","author":"D Schlondorff","year":"1993","unstructured":"Schlondorff, D. Cellular mechanisms of lipid injury in the glomerulus. Am. J. Kidney Dis. 22, 72\u201382 (1993).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2017155_CR89","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1046\/j.1523-1755.1999.07113.x","volume":"71","author":"Y Nishida","year":"1999","unstructured":"Nishida, Y., Oda, H. & Yorioka, N. Effect of lipoproteins on mesangial cell proliferation. Kidney Int. Suppl. 71, S51\u2013S53 (1999).","journal-title":"Kidney Int. Suppl."},{"key":"BFnrneph2017155_CR90","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1046\/j.1523-1755.2001.00720.x","volume":"59","author":"FT Stevenson","year":"2001","unstructured":"Stevenson, F. T., Shearer, G. C. & Atkinson, D. N. Lipoprotein-stimulated mesangial cell proliferation and gene expression are regulated by lipoprotein lipase. Kidney Int. 59, 2062\u20132068 (2001).","journal-title":"Kidney Int."},{"key":"BFnrneph2017155_CR91","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1046\/j.1523-1755.2001.00478.x","volume":"59","author":"GC Shearer","year":"2001","unstructured":"Shearer, G. C. et al. Hypoalbuminemia and proteinuria contribute separately to reduced lipoprotein catabolism in the nephrotic syndrome. Kidney Int. 59, 179\u2013189 (2001).","journal-title":"Kidney Int."},{"key":"BFnrneph2017155_CR92","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s10753-014-0058-0","volume":"38","author":"S Zhong","year":"2015","unstructured":"Zhong, S. et al. Inflammatory stress exacerbated mesangial foam cell formation and renal injury via disrupting cellular cholesterol homeostasis. Inflammation 38, 959\u2013971 (2015).","journal-title":"Inflammation"},{"key":"BFnrneph2017155_CR93","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1681\/ASN.2011040388","volume":"22","author":"JB Kopp","year":"2011","unstructured":"Kopp, J. B. et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J. Am. Soc. Nephrol. 22, 2129\u20132137 (2011).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2017155_CR94","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1126\/science.1193032","volume":"329","author":"G Genovese","year":"2010","unstructured":"Genovese, G. et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329, 841\u2013845 (2010).","journal-title":"Science"},{"key":"BFnrneph2017155_CR95","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1681\/ASN.2010070730","volume":"21","author":"BI Freedman","year":"2010","unstructured":"Freedman, B. I. et al. The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans. J. Am. Soc. Nephrol. 21, 1422\u20131426 (2010).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2017155_CR96","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1056\/NEJMc1011678","volume":"364","author":"H Debiec","year":"2011","unstructured":"Debiec, H. & Ronco, P. PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. N. Engl. J. Med. 364, 689\u2013690 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2017155_CR97","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","volume":"361","author":"LH Beck Jr","year":"2009","unstructured":"Beck, L. H. Jr et al. M-Type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N. Engl. J. Med. 361, 11\u201321 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2017155_CR98","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/nrneph.2014.87","volume":"10","author":"A Fornoni","year":"2014","unstructured":"Fornoni, A., Merscher, S. & Kopp, J. B. Lipid biology of the podocyte \u2014 new perspectives offer new opportunities. Nat. Rev. Nephrol. 10, 379\u2013388 (2014).","journal-title":"Nat. Rev. Nephrol."},{"key":"BFnrneph2017155_CR99","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1172\/JCI79641","volume":"125","author":"JJ Chung","year":"2015","unstructured":"Chung, J. J. et al. Albumin-associated free fatty acids induce macropinocytosis in podocytes. J. Clin. Invest. 125, 2307\u20132316 (2015).","journal-title":"J. Clin. Invest."},{"key":"BFnrneph2017155_CR100","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/nrneph.2015.76","volume":"11","author":"SJ Allison","year":"2015","unstructured":"Allison, S. J. Free fatty acid-induced macropinocytosis in podocytes. Nat. Rev. Nephrol. 11, 386 (2015).","journal-title":"Nat. Rev. Nephrol."},{"key":"BFnrneph2017155_CR101","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1038\/ki.2014.196","volume":"86","author":"S Agrawal","year":"2014","unstructured":"Agrawal, S., Guess, A. J., Chanley, M. A. & Smoyer, W. E. Albumin-induced podocyte injury and protection are associated with regulation of COX-2. Kidney Int. 86, 1150\u20131160 (2014).","journal-title":"Kidney Int."},{"key":"BFnrneph2017155_CR102","doi-asserted-by":"publisher","first-page":"F821","DOI":"10.1152\/ajprenal.00196.2010","volume":"299","author":"J Sieber","year":"2010","unstructured":"Sieber, J. et al. Regulation of podocyte survival and endoplasmic reticulum stress by fatty acids. Am. J. Physiol. Renal Physiol. 299, F821\u2013F829 (2010).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"BFnrneph2017155_CR103","doi-asserted-by":"publisher","first-page":"F401","DOI":"10.1152\/ajprenal.00454.2013","volume":"306","author":"K Kampe","year":"2014","unstructured":"Kampe, K., Sieber, J., Orellana, J. M., Mundel, P. & Jehle, A. W. Susceptibility of podocytes to palmitic acid is regulated by fatty acid oxidation and inversely depends on acetyl-CoA carboxylases 1 and 2. Am. J. Physiol. Renal Physiol. 306, F401\u2013F409 (2014).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"BFnrneph2017155_CR104","doi-asserted-by":"publisher","first-page":"e0142291","DOI":"10.1371\/journal.pone.0142291","volume":"10","author":"C Martinez-Garcia","year":"2015","unstructured":"Martinez-Garcia, C. et al. Renal lipotoxicity-associated inflammation and insulin resistance affects actin cytoskeleton organization in podocytes. PLoS ONE 10, e0142291 (2015).","journal-title":"PLoS ONE"},{"key":"BFnrneph2017155_CR105","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/ki.1988.3","volume":"33","author":"AA Eddy","year":"1988","unstructured":"Eddy, A. A. & Michael, A. F. Acute tubulointerstitial nephritis associated with aminonucleoside nephrosis. Kidney Int. 33, 14\u201323 (1988).","journal-title":"Kidney Int."},{"key":"BFnrneph2017155_CR106","first-page":"1111","volume":"138","author":"AA Eddy","year":"1991","unstructured":"Eddy, A. A., McCulloch, L., Liu, E. & Adams, J. A relationship between proteinuria and acute tubulointerstitial disease in rats with experimental nephrotic syndrome. Am. J. Pathol. 138, 1111\u20131123 (1991).","journal-title":"Am. J. Pathol."},{"key":"BFnrneph2017155_CR107","doi-asserted-by":"publisher","first-page":"E1868","DOI":"10.3390\/ijms17111868","volume":"17","author":"T Iwai","year":"2016","unstructured":"Iwai, T. et al. Stearoyl-CoA desaturase-1 protects cells against lipotoxicity-mediated apoptosis in proximal tubular cells. Int. J. Mol. Sci. 17, E1868 (2016).","journal-title":"Int. J. Mol. Sci."},{"key":"BFnrneph2017155_CR108","doi-asserted-by":"publisher","first-page":"F351","DOI":"10.1152\/ajprenal.00223.2015","volume":"310","author":"C Li","year":"2016","unstructured":"Li, C. et al. Intrarenal renin-angiotensin system mediates fatty acid-induced ER stress in the kidney. Am. J. Physiol. Renal Physiol. 310, F351\u2013F363 (2016).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"BFnrneph2017155_CR109","first-page":"10653","volume":"8","author":"N Zuo","year":"2015","unstructured":"Zuo, N., Zheng, X., Liu, H. & Ma, X. Fenofibrate, a PPAR\u03b1 agonist, protect proximal tubular cells from albumin-bound fatty acids induced apoptosis via the activation of NF-kB. Int. J. Clin. Exp. Pathol. 8, 10653\u201310661 (2015).","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"BFnrneph2017155_CR110","doi-asserted-by":"publisher","first-page":"F896","DOI":"10.1152\/ajprenal.00484.2013","volume":"306","author":"C Ruggiero","year":"2014","unstructured":"Ruggiero, C. et al. Albumin-bound fatty acids but not albumin itself alter redox balance in tubular epithelial cells and induce a peroxide-mediated redox-sensitive apoptosis. Am. J. Physiol. Renal Physiol. 306, F896\u2013F906 (2014).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"BFnrneph2017155_CR111","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","volume":"335","author":"FM Sacks","year":"1996","unstructured":"Sacks, F. M. et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 335, 1001\u20131009 (1996).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2017155_CR112","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","volume":"32","author":"Z Reiner","year":"2011","unstructured":"Reiner, Z. et al. ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur. Heart J. 32, 1769\u20131818 (2011).","journal-title":"Eur. Heart J."},{"key":"BFnrneph2017155_CR113","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/BF00868751","volume":"9","author":"A Bagga","year":"1995","unstructured":"Bagga, A., Sharma, A. & Srivastava, R. N. Inefficacy of pefloxacin in steroid-responsive nephrotic syndrome. Pediatr. Nephrol. 9, 793\u2013794 (1995).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2017155_CR114","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1038\/ki.1994.349","volume":"46","author":"WF Keane","year":"1994","unstructured":"Keane, W. F. Lipids and the kidney. Kidney Int. 46, 910\u2013920 (1994).","journal-title":"Kidney Int."},{"key":"BFnrneph2017155_CR115","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1046\/j.1523-1755.1999.00773.x","volume":"56","author":"BF Culleton","year":"1999","unstructured":"Culleton, B. F. et al. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int. 56, 2214\u20132219 (1999).","journal-title":"Kidney Int."},{"key":"BFnrneph2017155_CR116","volume-title":"Acute Renal Failure: A Companion to Brenner & Rector's The Kidney","author":"RJ Falk","year":"2001","unstructured":"Falk, R. J. in Acute Renal Failure: A Companion to Brenner & Rector's The Kidney (eds Molitoris, B. A. & Finn, W.) (Saunders, 2001)."},{"key":"BFnrneph2017155_CR117","doi-asserted-by":"publisher","first-page":"S142","DOI":"10.1053\/ajkd.1998.v32.pm9820472","volume":"32","author":"BL Kasiske","year":"1998","unstructured":"Kasiske, B. L. Hyperlipidemia in patients with chronic renal disease. Am. J. Kidney Dis. 32, S142\u2013S156 (1998).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2017155_CR118","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/ki.1993.292","volume":"44","author":"JD Ordonez","year":"1993","unstructured":"Ordonez, J. D., Hiatt, R. A., Killebrew, E. J. & Fireman, B. H. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int. 44, 638\u2013642 (1993).","journal-title":"Kidney Int."},{"key":"BFnrneph2017155_CR119","doi-asserted-by":"publisher","first-page":"81","DOI":"10.4103\/0974-2069.79633","volume":"4","author":"SP Suryawanshi","year":"2011","unstructured":"Suryawanshi, S. P., Das, B. & Patnaik, A. N. Myocardial infarction in children: two interesting cases. Ann. Pediatr. Cardiol. 4, 81\u201383 (2011).","journal-title":"Ann. Pediatr. Cardiol."},{"key":"BFnrneph2017155_CR120","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s00467-001-0793-y","volume":"17","author":"JM Silva","year":"2002","unstructured":"Silva, J. M. et al. Premature acute myocardial infarction in a child with nephrotic syndrome. Pediatr. Nephrol. 17, 169\u2013172 (2002).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2017155_CR121","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/0140-6736(92)90731-H","volume":"339","author":"G D'Amico","year":"1992","unstructured":"D'Amico, G. et al. Effect of vegetarian soy diet on hyperlipidaemia in nephrotic syndrome. Lancet 339, 1131\u20131134 (1992).","journal-title":"Lancet"},{"key":"BFnrneph2017155_CR122","first-page":"315","volume":"40","author":"MG Gentile","year":"1993","unstructured":"Gentile, M. G. et al. Treatment of proteinuric patients with a vegetarian soy diet and fish oil. Clin. Nephrol. 40, 315\u2013320 (1993).","journal-title":"Clin. Nephrol."},{"key":"BFnrneph2017155_CR123","doi-asserted-by":"publisher","first-page":"445","DOI":"10.5414\/CN107450","volume":"77","author":"S Bell","year":"2012","unstructured":"Bell, S., Cooney, J., Packard, C. J., Caslake, M. J. & Deighan, C. J. The effect of omega-3 fatty acids on the atherogenic lipoprotein phenotype in patients with nephrotic range proteinuria. Clin. Nephrol. 77, 445\u2013453 (2012).","journal-title":"Clin. Nephrol."},{"key":"BFnrneph2017155_CR124","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1681\/ASN.V361321","volume":"3","author":"AV Hall","year":"1992","unstructured":"Hall, A. V. et al. Omega-3 fatty acid supplementation in primary nephrotic syndrome: effects on plasma lipids and coagulopathy. J. Am. Soc. Nephrol. 3, 1321\u20131329 (1992).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2017155_CR125","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/S0140-6736(88)90870-7","volume":"2","author":"AJ Rabelink","year":"1988","unstructured":"Rabelink, A. J., Hene, R. J., Erkelens, D. W., Joles, J. A. & Koomans, H. A. Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidaemia of nephrotic syndrome. Lancet 2, 1335\u20131338 (1988).","journal-title":"Lancet"},{"key":"BFnrneph2017155_CR126","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/ki.1993.358","volume":"44","author":"ME Thomas","year":"1993","unstructured":"Thomas, M. E. et al. Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria. Kidney Int. 44, 1124\u20131129 (1993).","journal-title":"Kidney Int."},{"key":"BFnrneph2017155_CR127","first-page":"143","volume":"5","author":"S M.","year":"2004","unstructured":"M., S. et al. Evaluation of effects of lovastatin on hyercholesterolaemia and renl functions in nephrotic syndrome. Indian Acad. Clin. Med. 5, 143\u2013146 (2004).","journal-title":"Indian Acad. Clin. Med."},{"key":"BFnrneph2017155_CR128","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1159\/000065021","volume":"91","author":"OA Gheith","year":"2002","unstructured":"Gheith, O. A. et al. Impact of treatment of dyslipidemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. Nephron 91, 612\u2013619 (2002).","journal-title":"Nephron"},{"key":"BFnrneph2017155_CR129","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10157-008-0033-x","volume":"12","author":"O Gheith","year":"2008","unstructured":"Gheith, O., Sheashaa, H., Abdelsalam, M., Shoeir, Z. & Sobh, M. Efficacy and safety of Monascus purpureus Went rice in subjects with secondary hyperlipidemia. Clin. Exp. Nephrol. 12, 189\u2013194 (2008).","journal-title":"Clin. Exp. Nephrol."},{"key":"BFnrneph2017155_CR130","doi-asserted-by":"publisher","first-page":"S113","DOI":"10.1046\/j.1523-1755.1999.07128.x","volume":"71","author":"CJ Olbricht","year":"1999","unstructured":"Olbricht, C. J., Wanner, C., Thiery, J. & Basten, A. Simvastatin in nephrotic syndrome. Kidney Int. Suppl. 71, S113\u2013S116 (1999).","journal-title":"Kidney Int. Suppl."},{"key":"BFnrneph2017155_CR131","first-page":"CD005425","volume":"12","author":"X Kong","year":"2013","unstructured":"Kong, X. et al. Lipid-lowering agents for nephrotic syndrome. Cochrane Database Syst. Rev. 12, CD005425 (2013).","journal-title":"Cochrane Database Syst. Rev."},{"key":"BFnrneph2017155_CR132","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","volume":"377","author":"C Baigent","year":"2011","unstructured":"Baigent, C. et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377, 2181\u20132192 (2011).","journal-title":"Lancet"},{"key":"BFnrneph2017155_CR133","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S0272-6386(86)80164-0","volume":"8","author":"A Valeri","year":"1986","unstructured":"Valeri, A., Gelfand, J., Blum, C. & Appel, G. B. Treatment of the hyperlipidemia of the nephrotic syndrome: a controlled trial. Am. J. Kidney Dis. 8, 388\u2013396 (1986).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2017155_CR134","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/ki.1989.189","volume":"36","author":"GC Groggel","year":"1989","unstructured":"Groggel, G. C., Cheung, A. K., Ellis-Benigni, K. & Wilson, D. E. Treatment of nephrotic hyperlipoproteinemia with gemfibrozil. Kidney Int. 36, 266\u2013271 (1989).","journal-title":"Kidney Int."},{"key":"BFnrneph2017155_CR135","first-page":"40","volume":"44","author":"M Buyukcelik","year":"2002","unstructured":"Buyukcelik, M. et al. The effects of gemfibrozil on hyperlipidemia in children with persistent nephrotic syndrome. Turk. J. Pediatr. 44, 40\u201344 (2002).","journal-title":"Turk. J. Pediatr."},{"key":"BFnrneph2017155_CR136","doi-asserted-by":"publisher","first-page":"20B","DOI":"10.1016\/j.amjcard.2008.02.029","volume":"101","author":"VS Kamanna","year":"2008","unstructured":"Kamanna, V. S. & Kashyap, M. L. Mechanism of action of niacin. Am. J. Cardiol. 101, 20B\u201326B (2008).","journal-title":"Am. J. Cardiol."},{"key":"BFnrneph2017155_CR137","first-page":"415","volume":"8","author":"BA Phan","year":"2012","unstructured":"Phan, B. A., Dayspring, T. D. & Toth, P. P. Ezetimibe therapy: mechanism of action and clinical update. Vasc. Health Risk Manag. 8, 415\u2013427 (2012).","journal-title":"Vasc. Health Risk Manag."},{"key":"BFnrneph2017155_CR138","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1056\/NEJMoa0800742","volume":"358","author":"JJ Kastelein","year":"2008","unstructured":"Kastelein, J. J. et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med. 358, 1431\u20131443 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2017155_CR139","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/BF00862065","volume":"10","author":"JE Coleman","year":"1996","unstructured":"Coleman, J. E. & Watson, A. R. Hyperlipidaemia, diet and simvastatin therapy in steroid-resistant nephrotic syndrome of childhood. Pediatr. Nephrol. 10, 171\u2013174 (1996).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2017155_CR140","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/S0022-3476(97)70213-0","volume":"130","author":"SA Sanjad","year":"1997","unstructured":"Sanjad, S. A., al-Abbad, A. & al-Shorafa, S. Management of hyperlipidemia in children with refractory nephrotic syndrome: the effect of statin therapy. J. Pediatr. 130, 470\u2013474 (1997).","journal-title":"J. Pediatr."},{"key":"BFnrneph2017155_CR141","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1053\/j.ajkd.2003.08.012","volume":"42","author":"M Hattori","year":"2003","unstructured":"Hattori, M. et al. A combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children. Am. J. Kidney Dis. 42, 1121\u20131130 (2003).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2017155_CR142","doi-asserted-by":"publisher","first-page":"S122","DOI":"10.1046\/j.1523-1755.1999.07130.x","volume":"71","author":"E Muso","year":"1999","unstructured":"Muso, E. et al. Low density lipoprotein apheresis therapy for steroid-resistant nephrotic syndrome. Kansai-FGS-Apheresis Treatment (K-FLAT) Study Group. Kidney Int. Suppl. 71, S122\u2013S125 (1999).","journal-title":"Kidney Int. Suppl."},{"key":"BFnrneph2017155_CR143","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s10157-014-0996-8","volume":"19","author":"E Muso","year":"2015","unstructured":"Muso, E. et al. Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome: evidence from the short-term results from the POLARIS Study. Clin. Exp. Nephrol. 19, 379\u2013386 (2015).","journal-title":"Clin. Exp. Nephrol."},{"key":"BFnrneph2017155_CR144","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1159\/000437338","volume":"5","author":"E Muso","year":"2015","unstructured":"Muso, E. et al. A prospective observational survey on the long-term effect of LDL apheresis on drug-resistant nephrotic syndrome. Nephron Extra 5, 58\u201366 (2015).","journal-title":"Nephron Extra"},{"key":"BFnrneph2017155_CR145","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/1744-9987.12561","volume":"21","author":"H Suzuki","year":"2017","unstructured":"Suzuki, H., Tsukamoto, T. & Muso, E. Rituximab-resistant nephrotic syndrome with successful induction of remission by low-density lipoprotein apheresis. Ther. Apher. Dial. 21, 295\u2013296 (2017).","journal-title":"Ther. Apher. Dial."},{"key":"BFnrneph2017155_CR146","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02314442 (2015)."},{"key":"BFnrneph2017155_CR147","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1609243","volume":"376","author":"K Fitzgerald","year":"2017","unstructured":"Fitzgerald, K. et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N. Engl. J. Med. 376, 41\u201351 (2017).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2017155_CR148","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1093\/ndt\/gft439","volume":"29","author":"S Liu","year":"2014","unstructured":"Liu, S. & Vaziri, N. D. Role of PCSK9 and IDOL in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndrome. Nephrol. Dial. Transplant. 29, 538\u2013543 (2014).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2017155_CR149","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03004001 (2017)."},{"key":"BFnrneph2017155_CR150","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s12882-017-0644-0","volume":"18","author":"Y Awanami","year":"2017","unstructured":"Awanami, Y. et al. Successful treatment of a patient with refractory nephrotic syndrome with PCSK9 inhibitors: a case report. BMC Nephrol. 18, 221 (2017).","journal-title":"BMC Nephrol."},{"key":"BFnrneph2017155_CR151","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1001\/jama.2016.11004","volume":"316","author":"DS Kazi","year":"2016","unstructured":"Kazi, D. S. et al. Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. JAMA 316, 743\u2013753 (2016).","journal-title":"JAMA"},{"key":"BFnrneph2017155_CR152","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1161\/01.CIR.0000136023.70841.0F","volume":"110","author":"ND Vaziri","year":"2004","unstructured":"Vaziri, N. D. & Liang, K. H. Acyl-coenzyme A:cholesterol acyltransferase inhibition ameliorates proteinuria, hyperlipidemia, lecithin-cholesterol acyltransferase, SRB-1, and low-denisty lipoprotein receptor deficiencies in nephrotic syndrome. Circulation 110, 419\u2013425 (2004).","journal-title":"Circulation"},{"key":"BFnrneph2017155_CR153","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1161\/01.CIR.0000147777.12010.EF","volume":"110","author":"JC Tardif","year":"2004","unstructured":"Tardif, J. C. et al. Effects of the acyl coenzyme A: cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation 110, 3372\u20133377 (2004).","journal-title":"Circulation"},{"key":"BFnrneph2017155_CR154","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02235857 (2016)."},{"key":"BFnrneph2017155_CR155","unstructured":"[No authors listed.] Chapter 2: General principles in the management of glomerular disease. Kidney Int. Suppl. 2, 156\u2013162 (2012)."},{"key":"BFnrneph2017155_CR156","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1007\/s00467-004-1460-x","volume":"19","author":"BL Lechner","year":"2004","unstructured":"Lechner, B. L., Bockenhauer, D., Iragorri, S., Kennedy, T. L. & Siegel, N. J. The risk of cardiovascular disease in adults who have had childhood nephrotic syndrome. Pediatr. Nephrol. 19, 744\u2013748 (2004).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2017155_CR157","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00004466 (2017)."},{"key":"BFnrneph2017155_CR158","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01845428 (2017)."}],"updated-by":[{"DOI":"10.1038\/nrneph.2017.175","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000}}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2017.155.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2017.155","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/nrneph.2017.155","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2017.155.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:50:16Z","timestamp":1684457416000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneph.2017.155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,27]]},"references-count":158,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["BFnrneph2017155"],"URL":"https:\/\/doi.org\/10.1038\/nrneph.2017.155","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,27]]},"assertion":[{"value":"27 November 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2017","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the version of this article originally published online, the affiliations of the authors were incorrect. This error has now been corrected in the print and online versions.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}